What about a patient with TG 600 who also fits the REDUCE-IT profile (except for VHTG)?
After we retire gV then we can fight Lovaza.
What should happen in an ideal world is that Lovaza should be banned, period. If not banned, it should only be prescribed with those with > 500 and no CVD risk. Good luck finding those folks.
My layman view: Risk of pancreatitis is more important than CVD risk in case of VHTG (TG > 500). The primary aim of the treatment is to avoid / prevent pancreatitis, decrease the TG level. For this, Lovaza is superior to Vascepa.
Below TG 500, risk of pancreatitis does not exist anymore, the focus is the CVD risk ... Vascepa is the solution.
Both - Vascepa and Lovaza - have the function: - pancreatitis: Lovaza - CVD risk: Vascepa (In case of TG > 500 and CVD risk, the CVD risk "does not" matter").
Amen Raf-all these other suggestions are educated lunacy and about as practical as wrapping your arm around your head to touch your nose. These third-party payors have turned thinking prescribers into thoughtless paid monkeys.
What should happen in an ideal world is that Lovaza should be banned, period. If not banned, it should only be prescribed with those with > 500 and no CVD risk. Good luck finding those folks.
Would doctors have to put what the actual trig number on PA or could they just say ‘trigs >150’ as part of the PA. Or would they have to state >150 but <500 trigs to get approval. I agree that it’s still great news and the wording may be adjusted later to capture those with trigs>500 at a later time.